Counterpoint: Better radiation treatment of non-small cell lung cancer using new techniques without elective nodal irradiation

Seminars in Radiation Oncology

Volumn 10, Issue 4, 2000, Pages 315-323

  Williams, Todd E ^a   Thomas Jr, Charles R ^a   Turrisi III, Andrew T ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; TEGAFUR; UFT; URACIL; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; ENDOSCOPIC ECHOGRAPHY; ESOPHAGITIS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION INJURY; RADIATION PNEUMONIA; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0033784888     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2000.9613     Document Type: Article

References (73)

1. Improved survival of patients with unresectable non-small cell bronchogenic carcinoma by an innovated high-dose en-bloc radiotherapeutic approach
2. The value of regional nodal radiotherapy (dose/volume) in the treatment of unresectable non-small cell lung cancer: An RTOG analysis
3. Patters of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung
4. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat cell carcinoma of the lung
5. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: Report by the Radiation Therapy Oncology Group
6. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable non-small cell lung cancer (NSCLC)
7. Response, toxicity, failure patterns, and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung
8. Tolerance of normal tissue to therapeutic irradiation
9. Effects of Postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung
10. The impact of surgical adjuvant thoracic radiation therapy for non-small cell lung cancer patients with mediastinal nodal involvement
11. Postoperative radiotherapy in non-small cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomized controlled trials
12. A controlled study of postoperative radiotherapy for patients with completely resected non-small cell lung carcinoma
13. The role of post-operative radiotherapy in non-small cell lung cancer: A multicenter randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease
14. Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomized phase II study
15. Phase III comparison of sequential vs concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC): Initial report of radiation therapy oncology group (RTOG) 9410
16. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer
17. A randomized phase I/II trial of Hyperfractionated radiation therapy with total doses of 60.0Gy to 79.2Gy: Possible survival benefit with ≥69.6Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small cell lung carcinoma: Report of the Radiation Therapy Oncology Group 83-11
18. Dose response of squamous cell carcinomas of the upper respiratory and digestive tracts
19. Autopsy findings in lung cancer treated with megavoltage radiotherapy
20. Cisplatin-based chemotherapy (CT) in patients with locally advanced non-small cell lung cancer (NSCLC): Late analysis of a French randomized trial
21. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: A retrospective analysis of 149 patients
22. Curative idiotherapy for technically operable stage I non-small cell lung cancer
23. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer
24. Limited field irradiation for medically inoperable patients with peripheral stage I non-small cell lung cancer
25. Hyperfractionated radiotherapy alone for clinical stage I non-small cell lung cancer
26. Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer
27. Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer
28. Local irradiation alone for peripheral stage I lung cancer: Could we omit the elective regional nodal irradiation?
29. Radiotherapy along for medically inoperable stage I non-small cell lung cancer: The Duke Experience
30. Radiation Therapy along for stage I non-small cell lung cancer
31. Radiotherapy as an alternative to surgery in elderly patients with respectable lung cancer
32. Radiation therapy in the management of medically inoperable carcinoma of the lung: Results and implications for future treatment strategies
33. Dose escalation in non-small cell lung cancer using 3-dimensional conformal radiation therapy: Update of a phase I trial
34. Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer
35. Dose escalation of chart in non-small cell lung cancer: Is three-dimensional conformal radiation therapy really necessary?
36. Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer: Implications in the inoperable and three-dimensional dose-escalation settings
37. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer
38. The toxicity of elective nodal irradiation in the definitive treatment of non-small cell carcinoma of the lung
39. Dose escalation for non-small cell lung cancer using conformal radiation therapy
40. Reassessment of radiation therapy for the management of lung cancer in patients with chronic pulmonary disease
41. Sites of recurrence in resected stage I non-small cell lung cancer: A guide for future studies
42. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer
43. Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: A randomized study
44. Adjuvant chemotherapy after complete resection in non-small cell lung cancer
45. A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study)
46. Postoperative adjuvant chemotherapy in non-small cell lung cancer: Prognostic value of DNA ploidy and postrecurrent survival
47. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure
48. Stage I non-small cell lung cancer: A multivariate analysis of treatment methods and patterns of recurrence
49. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer (Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group). Clinical investigations
50. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): Analysis of radiation therapy oncology group (RTOG) trials
51. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in RTOG 88-08/ECOG 4588
52. Improved survival in stage III non-small cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial
53. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
54. Imaging lung cancer
55. Staging non-small cell lung cancer with whole body PET
56. FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients
57. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s - Meta-analytic comparison of PET and CT
58. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer
59. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localization of regional lymph node metastases? The Leuven Lung Cancer Group
60. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small cell lung cancer: A prospective pilot study. The Leuven Lung Cancer Group
61. Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography scan in non-small cell lung cancer: An analysis of 125 cases
62. Early F-18 FDG-PET response to radical chemoradiotherapy correlates strongly with survival in unresectable non-small cell lung cancer
63. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3cm) lymph node lesions
64. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis
65. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer
66. Impact of PET scan in lung cancer radiotherapy planning
67. American Thoracic Society: Clinical staging of primary lung cancer
68. Endoscopic ultrasound with fine-needle aspiration in the diagnosis and staging of lung cancer
69. Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography, and computed tomography in the preoperative staging of non-small cell lung cancer: A comparison study
70. Role of transesophageal endosonography-guided fine-needle aspiration in the diagnosis of lung cancer
71. Transesophageal biopsy of mediastinal and pulmonary tumors by means of endoscopic ultrasound guidance
72. Randomized controlled trial (RCT) to evaluate the cost-effectiveness of positron emission tomography (PET) added to conventional diagnosis in non-small cell lung cancer (NSCLC)
73. Cost-efficacy of endoscopic ultrasonography with fine-needle aspiration vs. mediastinotomy in patients with lung cancer and suspected mediastinal adenopathy